510(k) Report

510(k) · Cleared

Cleared

Annalise Enterprise CTB Triage Trauma

K231767510(k) TraditionalCleared Sep 22, 202398-day reviewClass II21 CFR 892.2080

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Annalise-Ai Pty, Ltd. · QAS Radiological Computer-Assisted Triage And Notification Software

Cleared on Sep 22, 2023 as substantially equivalent to K223240 (Annalise-Ai Pty, Ltd., 2023) after a 98-day review. Its family tree reaches back 4 generations to 2018.

Decided
Sep 22, 2023
Review
98 days
Class
Class II
Product code
QAS
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to DEN170073 (2018). No later device cites it as a predicate yet.

  1. Root · 4 generations backDEN170073 ContaCTViz.Al, Inc. · 2018
  2. 3 generations backK180647 BriefCaseAidoc Medical, Ltd. · 2018
  3. 2 generations backK211179 InferRead CT Stroke.AIInfervision Medical Technology Co., Ltd. · 2021
  4. 1 generation backK223240 Annalise Enterprise CTB Triage TraumaAnnalise-Ai Pty, Ltd. · 2023
  5. This deviceK231767 Annalise Enterprise CTB Triage TraumaAnnalise-Ai Pty, Ltd. · 2023
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4DEN170073ContaCTViz.Al, Inc.2018—
−3K180647BriefCaseAidoc Medical, Ltd.2018—
−2K211179InferRead CT Stroke.AIInfervision Medical Technology Co., Ltd.2021—
−1K223240Annalise Enterprise CTB Triage TraumaAnnalise-Ai Pty, Ltd.2023—
0 (this device)K231767Annalise Enterprise CTB Triage TraumaAnnalise-Ai Pty, Ltd.2023—
FIG. 1 — Lineage of K231767, 2018–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QAS? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QAS device

  1. #1 K203508 BriefCasescore 25.5 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K223240Annalise Enterprise CTB Triage Trauma
Summary page 5
…e QAS III. PREDICATE DEVICE Manufacturer Name Annalise-AI Pty Ltd Device Name Annalise Enterprise CTB Triage Trauma 510(k) reference K223240 Classification Name Radiological computer aided triage and notification software (21CFR892.2080) Reg…
Annalise-Ai Pty, Ltd.2023—

Also cleared against K223240: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 5 years and passes through 4 companies; a new generation was cleared every 1.6 years on median.
  • None of the 4 ancestors has a recall.
  • 1 other device also cites its predicate K223240.

How does its category compare?

All QAS devices

QAS Radiological Computer-Assisted Triage And Notification Software: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · QAS

15in 2025

2018: 32019: 52020: 122021: 52022: 152023: 112024: 122025: 152026 (partial year): 11
2007high 15 (2022) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QAS

101in 2025

2019: 111 days median2020: 112 days median2021: 86 days median2022: 116 days median2023: 98 days median2024: 136 days median2025: 101 days median2026 (partial year): 104 days median
2007high 136 (2024) · low 86 (2021)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QAS

No recall names QAS since 2007.

Adverse event reports per year · QAS

No MAUDE report names QAS since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20183—00
2019511100
20201211200
202158600
20221511600
2023119800
20241213600
20251510100
2026111040—

What is it indicated for?

Intended context: Annalise Enterprise is a device designed to be used in the medical care environment to aid in triage and prioritization of studies with features suggestive of the following finding: vasogenic edema The device analyzes studies using an artificial intelligence algorithm to identify the finding. It makes study-level output available to an order and imaging management system for worklist prioritization or triage. The device is not intended…

Read the full statement (171 words)

Intended context:

Annalise Enterprise is a device designed to be used in the medical care environment to aid in triage and prioritization of studies with features suggestive of the following finding:

vasogenic edema

The device analyzes studies using an artificial intelligence algorithm to identify the finding. It makes study-level output available to an order and imaging management system for worklist prioritization or triage.

The device is not intended to direct attention to specific portions of an image and only provides notification for the suspected finding.

Its results are not intended:

* to be used on a standalone basis for clinical decision making

* to rule out a specific finding, or otherwise preclude clinical assessment of CTB studies

Intended modality:

Annalise Enterprise identifies the suspected finding in non-contrast brain CT studies.

Intended user:

The device is intended to be used by trained clinicians who, as part of their scope of practice, are qualified to interpret brain CT studies.

Intended patient population:

The intended population is patients who are 22 years or older.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K231767: Annalise Enterprise CTB Triage Trauma.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K231767

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026